odronextamab
regeneron
['odronextamab', 'lymsm', 'elm-2']
#17icml silvana novelli, presents results from the elm-2 study analyzing odronextamab in patients with r/r fl post 2 or more lines of therapy. for this cohort where prognosis is typically poor, odronextamab demonstrated efficacy and manageable safety profile #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm